# A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma

> **NCT00661336** · PHASE1 · WITHDRAWN · sponsor: **Duke University**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **DRUG:** buthionine sulfoximine
- **DRUG:** melphalan
- **GENETIC:** microarray analysis
- **OTHER:** high performance liquid chromatography
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT00661336
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-04
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was withdrawn due to lack of patients.
- **Last updated:** 2015-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00661336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00661336, "A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT00661336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*